ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,101 to 3,120 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Folic Acid and Zinc Supplementation vs Placebo: serious adverse events7 of 1,185

5 of 1,185

0.2 points

-0.5 to 0.8

2,370NCT01857310

Folic Acid and Zinc Supplementation Trial (FAZST)

Plecanatide 3 mg vs Plecantide 6 mg: Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of Plecanatide14 of 224

111 of 2,146

1.1 points

-1.6 to 5.1

2,370NCT01919697

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Plecanatide 3 mg vs Plecantide 6 mg: Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE)123 of 224

620 of 2,146

26.0 points

19.2 to 32.7

2,370NCT01919697

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Plecanatide 3 mg vs Plecantide 6 mg: Summary of Treatment-Emergent Laboratory Abnormalities With At Least a 1-grade Shift From Baseline192 of 224

1,498 of 2,146

15.9 points

10.4 to 20.4

2,370NCT01919697

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Plecanatide 3 mg vs Plecanatide 6 mg: deaths from any cause0 of 224

1 of 2,146

-0.0 points

-0.3 to 1.6

2,370NCT01919697

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Plecanatide 3 mg vs Plecanatide 6 mg: serious adverse events8 of 224

32 of 2,146

2.1 points

0.2 to 5.4

2,370NCT01919697

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Intervention vs Usual Care: Medically Treated Falls328 of 1,106

349 of 1,261

2.0 points

-1.7 to 5.6

2,367NCT05689554

Reducing CNS-Active Medications to Prevent Falls and Injuries in Older Adults

Intervention vs Usual Care: deaths from any cause86 of 1,106

72 of 1,261

2.1 points

0.0 to 4.1

2,367NCT05689554

Reducing CNS-Active Medications to Prevent Falls and Injuries in Older Adults

Intervention vs Usual Care: serious adverse events10 of 1,106

4 of 1,261

0.6 points

-0.1 to 1.4

2,367NCT05689554

Reducing CNS-Active Medications to Prevent Falls and Injuries in Older Adults

Information vs Usual Care: deaths from any cause39 of 1,198

35 of 1,166

0.3 points

-1.2 to 1.7

2,364NCT04852055

Effect of an Advance Care Planning Intervention

Transdisciplinary Approach vs Multidisciplinary Approach: Depressive Symptoms37 of 680

90 of 1,676

0.1 points

-1.8 to 2.3

2,356NCT03442322

Optimizing Care for Patients With Dementia

BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: Time to First Severe Asthma Exacerbation, While on Treatment Strategy (Participants Aged >=18 Years)71 of 1,180

126 of 1,173

-4.7 points

-7.0 to -2.5

2,353NCT05505734

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: Time to First Severe Asthma Exacerbation, Treatment Policy Strategy (Participants Aged >=18 Years)73 of 1,180

131 of 1,173

-5.0 points

-7.3 to -2.7

2,353NCT05505734

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

Folic Acid 4 mg vs Placebo: Spontaneous Abortion27 of 1,172

21 of 1,180

0.5 points

-0.6 to 1.7

2,352NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Roflumilast vs Placebo: serious adverse events180 of 1,178

162 of 1,174

1.5 points

-1.4 to 4.3

2,352NCT01443845

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

Folic Acid 4 mg vs Placebo: Premature Rupture of Membranes215 of 1,169

224 of 1,180

-0.6 points

-3.7 to 2.6

2,349NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Folic Acid 4 mg vs Placebo: Placenta Abruption12 of 1,169

19 of 1,179

-0.6 points

-1.6 to 0.4

2,348NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Comparator: ENGERIX-B Hep B Vaccination vs Pooled Sci-B-Vac®: Seroprotection Rate (SPR) of Anti-HBs at Day 196 for Sci-B-Vac® Compared to Day 196 for Engerix-B® (Per Protocol Set 2)561 of 592

1,740 of 1,753

-4.5 points

-6.6 to -2.9

2,345NCT03408730

Lot-to-lot Consistency of Sci-B-Vac™ in Adults

Referred Subjects vs Not Referred Subjects: Percentage of Post-Acute MI Patients Who Are Referred for Sudden Cardiac Death Risk Stratification > Risk (SCD) Stratification and Management236 of 1,170

934 of 1,170

-59.7 points

-62.8 to -56.3

2,340NCT03715790

Improve SCA Bridge Study

Self-collected Specimens vs Physician-sampled Specimens: Percentage of a Valid Specimen, According to the Presence of the Beta-globin Gene in Specimens1,170 of 1,170

1,170 of 1,170

0.0 points

-0.3 to 0.3

2,340NCT04472377

HPV Typing Between Self- and Physician-sampled

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=156"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=156

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01857310-sae",
        "title": "Folic Acid and Zinc Supplementation vs Placebo: serious adverse events",
        "summary": "7 of 1185 against 5 of 1185; risk difference 0.2 points, 95% interval -0.5 to 0.8; NCT01857310, Folic Acid and Zinc Supplementation Trial (FAZST)",
        "record": "/library/comparisons/NCT01857310-sae",
        "nct_id": "NCT01857310",
        "kind": "serious-adverse-events",
        "participants": 2370,
        "risk_difference": {
          "value": 0.0016877637130801688,
          "lower": -0.0047029480422807095,
          "upper": 0.008375283293623425
        },
        "group_1": "7 of 1,185",
        "group_2": "5 of 1,185",
        "difference": "0.2 points",
        "interval": "-0.5 to 0.8",
        "trial_title": "Folic Acid and Zinc Supplementation Trial (FAZST)"
      },
      {
        "id": "NCT01919697-0a6e7756",
        "title": "Plecanatide 3 mg vs Plecantide 6 mg: Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of Plecanatide",
        "summary": "14 of 224 against 111 of 2146; risk difference 1.1 points, 95% interval -1.6 to 5.1; NCT01919697, Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)",
        "record": "/library/comparisons/NCT01919697-0a6e7756",
        "nct_id": "NCT01919697",
        "kind": "outcome",
        "participants": 2370,
        "risk_difference": {
          "value": 0.010775862068965518,
          "lower": -0.01613908643881387,
          "upper": 0.05135773247189961
        },
        "group_1": "14 of 224",
        "group_2": "111 of 2,146",
        "difference": "1.1 points",
        "interval": "-1.6 to 5.1",
        "trial_title": "Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=157",
  "request_id": "aYhxdggrhW2rPNIY"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?